A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus.

J Family Med Prim Care · 2019 · PMC6482796 · PMID 31041232

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The cost-effectiveness for per unit reduction in FPG was highly significant in metformin plus glimepiride group though it was comparable for both the groups for per unit PPG reduction [ Table 5 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.